CDT Equity (CDT) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SciSparc is the larger company by market cap ($481,603 vs $437,033), about 1.1 times the size. On valuation, CDT Equity trades at a lower trailing P/E (0.0x vs 0.0x for SciSparc).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDT | SPRC |
|---|---|---|
| Share price | $0.23 | $0.1955 |
| Market cap | $437.03K | $481.60K |
| 1-day change | -13.89% | -34.83% |
| P/E ratio (TTM) | 0.00 | 0.00 |
| EPS (TTM) | $1,816,250.00 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.31M |
| Revenue growth (YoY) | — | -54.64% |
| Net income (latest FY) | $-39.22M | $-6.28M |
| Gross margin | — | 38.74% |
| Operating margin | — | -560.18% |
| Net margin | — | -481.16% |
| 52-week high | $291,250.00 | $29.88 |
| 52-week low | $0.223 | $0.167 |
| Distance from 52-week high | -100.00% | -99.35% |
| Average volume | 956.66K | 2.93M |
| Shares outstanding | 1.90M | 2.46M |
| Employees | 4 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SciSparc trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
CDT vs SPRC FAQ
Which is bigger, CDT Equity or SciSparc?
SciSparc (SPRC) is larger, with a market capitalization of $481.60K compared with $437.03K for CDT Equity (CDT).
Which has the lower P/E ratio, CDT or SPRC?
CDT has the lower trailing P/E at 0.0, versus 0.0 for SPRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are CDT Equity and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.